Drug Profile
Ophthalmic steroid - ISTA Pharmaceuticals
Latest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator ISTA Pharmaceuticals
- Class Steroids
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Ocular inflammation
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for phase-I development in Ocular-inflammation in USA
- 05 Aug 2013 Bausch & Lomb has been acquired by Valeant Pharmaceuticals International
- 06 Jun 2012 ISTA Pharmaceuticals has been acquired by Bausch & Lomb